The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

‘Holy grail of medicine’: Experimental drug promises to stop flu in its tracks—if it works in humans

| | October 25, 2019

We might be inching closer to a holy grail of medicine: an incredibly effective flu-killing drug that the virus can’t quickly adapt to. A new experimental treatment was able to rapidly reduce the flu virus in ferrets, but human trials are still a ways off.

For the researchers’ experiments, the ferrets were first infected with different types of flu—the kinds that cause us seasonal sniffles as well as the strain of flu behind a 2009 pandemic—then they were treated with varying oral doses of [the drug] EIDD-2801 a day into exposure.

They found that EIDD-2801 was able to dramatically reduce the viral load of these flu strains “by multiple orders of magnitude” within a day’s time, along with alleviating fever and other symptoms of infection—with its performance being comparable to or better than an existing antiviral used to treat flu. And when EIDD-2801 was given to the ferrets immediately before and after flu exposure, it prevented illness from showing up at all. Experiments involving human lung tissue created in a petri dish found similar evidence of EIDD-2801’s lethality.

Related article:  Drug weapons: Computer designed proteins prepare to battle the next pandemic

Read full, original post: Scientists Say Their Experimental Drug Knocks Out the Flu, in Animal Tests at Least

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend